New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 14, 2014
07:32 EDTPTX, GSK, POZNPernix Therapeutics to acquire TREXIMET tablets for migrain from GlaxoSmithKline
Pernix Therapeutics Holdings (PTX) announced that it has signed an agreement with GlaxoSmithKline (GSK) to acquire the U.S rights to Treximet for the acute treatment of migraine attacks with or without aura in adults. Pernix’s team of approximately 90 specialty sales professionals will support the sales and marketing of Treximet. The transaction: Adds immediate revenues and earnings, FY13 Treximet net sales $78.7M; Leverages Pernix’s existing sales presence and experience across psychiatry and neurology customers; Expected to nearly double Pernix revenues and provide EBITDA margins in excess of 30% on a FY14 pro forma basis; Pernix estimates pro forma FY15 total company revenues will exceed $230M with an EBITDA margin of over 40%. Pernix will make an upfront payment to GSK of $250M for the U.S rights to Treximet. GSK will assign to Pernix the Product Development and Commercialization Agreement between GSK and POZEN (POZN). POZEN and Pernix will amend the PDC Agreement to facilitate further development of Treximet. Pernix expects to begin sales of Treximet immediately following the closing of the transaction with its approximately 90 sales professionals to specific targets in the Neurology, Psychiatry and the Primary Care audiences. Pernix also plans to seek an extension of the exclusivity of Treximet with the first ever pediatric indication for any sumatriptan treatment, expected to file by the end of 2014, as well as additional life-cycle opportunities that are currently being explored. Pernix will pay GSK additional consideration of $17M upon receipt of updated FDA Written Request for pediatric exclusivity.
News For PTX;GSK;POZN From The Last 14 Days
Check below for free stories on PTX;GSK;POZN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 15, 2014
06:34 EDTGSKLawyer says GSK connected investigators to not appeal ruling, Reuters says
Defense lawyer Zhai Jian said GlaxoSmithKline connected corporate investigator Peter Humphrey and his American wife are not aiming to appeal a Chinese court's prison sentence ruling, according to Reuters, citing comments from Jian. Reference Link
August 13, 2014
16:19 EDTGSKOn The Fly: Closing Wrap
Subscribe for More Information
13:13 EDTGSKInterMune exploring sale after bids from Sanofi, Roche, Glaxo, Bloomberg says
InterMune (ITMN) is working with its financial advisers Goldman Sachs (GS) and Centerview Partners to evaluate takeover bids it has received from Sanofi (SNY), Roche (RHHBY), GlaxoSmithKline (GSK) and Actelion (ALIOF), said Bloomberg, citing people with knowledge of the matter. The report noted that one of the sources said Sanofi has so far shown the most interest in a deal for InterMune, whose shares are up more than 13% to $51.56 following the first headlines from the report. Reference Link
07:32 EDTPOZNHorizon Pharma, POZEN announce USPTO Notice of Allowance for VIMOVO
Subscribe for More Information
August 12, 2014
07:15 EDTGSKWHO says ethical to offer unproven interventions in light of Ebola outbreak
Subscribe for More Information
06:18 EDTGSKGSK CEO faces pressure as company deals with weak sales, allegations, WSJ says
Subscribe for More Information
August 11, 2014
12:57 EDTGSKGlaxoSmithKline facing new bribery allegations in Syria, Reuters reports
Subscribe for More Information
08:47 EDTGSKGlaxo to conduct Ebola vaccine trials later this year, Guardian says
Subscribe for More Information
08:37 EDTPTXPernix says closing of deal to acquire U.S. rights to Treximet delayed
Subscribe for More Information
08:34 EDTPTXPernix Therapeutics reports Q2 EPS (16c), two estimates (5c)
Subscribe for More Information
August 8, 2014
10:00 EDTPOZNOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Activision Blizzard (ATVI) upgraded to Buy from Neutral at Longbow... Allergan (AGN) upgraded to Outperform from Market Perform at Leerink... Andersons (ANDE) upgraded to Buy from Hold at Feltl... Arista Networks (ANET) upgraded to Buy from Neutral at Citigroup... Barrick Gold (ABX) upgraded to Conviction Buy from Buy at Goldman... Brinker (EAT) upgraded to Outperform from Market Perform at Raymond James... CF Industries (CF) upgraded to Buy from Hold at Feltl... CST Brands (CST) upgraded to Neutral from Underperform at Credit Suisse... Cimarex Energy (XEC) upgraded to Accumulate from Hold at KLR Group... Coca-Cola HBC (OCCH) upgraded to Buy from Hold at Deutsche Bank... Delek US (DK) upgraded to Outperform at Cowen... Fifth Street Finance (FSC) upgraded to Buy from Neutral at Guggenheim... Glimcher Realty Trust (GRT) upgraded to Buy from Neutral at BofA/Merrill... Goodrich Petroleum (GDP) upgraded to Strong Buy from Outperform at Raymond James... Monster Beverage (MNST) upgraded to Neutral from Underperform at Longbow... NIC Inc. (EGOV) upgraded to Outperform from Market Perform at Barrington... NVIDIA (NVDA) upgraded at Needham... POZEN (POZN) upgraded to Buy from Hold at Ascendiant... Power Solutions (PSIX) upgraded to Accumulate from Neutral at Global Hunter... Primoris (PRIM) upgraded to Buy from Hold at BB&T... Sierra Bancorp (BSRR) upgraded to Outperform from Market Perform at Raymond James... Sonus Networks (SONS) upgraded to Outperform from Market Perform at Barrington... Stone Energy (SGY) upgraded to Buy from Accumulate at KLR Group... Tornier (TRNX) upgraded at BMO Capital... Tyson Foods (TSN) upgraded to Buy from Hold at BB&T... WGL Holdings (WGL) upgraded to Buy from Hold at Brean Capital.
09:03 EDTGSKGlaxoSmithKline weakness creates buying opportunity, says Argus
Subscribe for More Information
06:18 EDTGSKRoyal Bank of Scotland's Hampton leads race to become new GSK chair, FT reports
Royal Bank of Scotland (RBS) Chairman Philip Hampton is the frontrunner to succeed Christopher Gent as chairman of GlaxoSmithKline (GSK), the Financial Times reports, citing sources. Gent will step down from his role at GSK next year. Hampton is not expected to step down from RBS until after May's general election, the sources say. Reference Link
05:37 EDTPOZNPOZEN upgraded to Buy from Hold at Ascendiant
Subscribe for More Information
August 7, 2014
07:42 EDTPOZNPOZEN plans to make future employee reductions
Subscribe for More Information
07:33 EDTPOZNPOZEN reports Q2 EPS 9c, one estimate 7c
Reports Q2 revenue $7.4M, one estimate $7.1M.
August 6, 2014
07:02 EDTGSKSynta Pharmaceuticals names Anne Whitaker as CEO, effective September 2
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use